United Therapeutics Corp. – Executive Shareholder Activity Overview
Context and Regulatory Framework
On October 19 and 20, 2026, United Therapeutics Corp. (NASDAQ: UNTH) filed Form 4 disclosures with the U.S. Securities and Exchange Commission (SEC) under accession numbers 0001106578‑26‑000166 and 0001106578‑26‑000167. These filings document a series of beneficial ownership changes involving the company’s principal executive, Martine A. Rothblatt, who holds the dual roles of chairperson and chief executive officer.
Under SEC rules, insider transactions of this nature are required to be reported to provide transparency for investors and to ensure compliance with Section 16 of the Securities Exchange Act of 1934. The filings explicitly note that the changes are not subject to additional Section 16 reporting requirements, nor do they involve equity swaps, thereby confirming that the transactions are straightforward purchases and disposals of company shares.
Summary of Transactions
| Date | Action | Shares | Price per Share | Total Value | Holding After |
|---|---|---|---|---|---|
| 10‑19‑2026 | Purchase | 9,500 | ~ $118 | ~$1.12 M | ~ 333,900 |
| 10‑19‑2026 | Sale | 300 | ~$530 | ~$159 k | ~ 333,600 |
| 10‑19‑2026 | Sale | 1,500 | ~$545 | ~$818 k | ~ 332,100 |
| 10‑20‑2026 | Sale | 2,000 | ~$540 | ~$1.08 M | ~ 330,100 |
| 10‑20‑2026 | Sale | 1,200 | ~$550 | ~$660 k | ~ 328,900 |
| 10‑20‑2026 | Sale | 800 | ~$530 | ~$424 k | ~ 328,100 |
| 10‑20‑2026 | Sale | 1,000 | ~$545 | ~$545 k | ~ 327,100 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 326,100 |
| 10‑20‑2026 | Sale | 1,000 | ~$530 | ~$530 k | ~ 325,100 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 323,900 |
| 10‑20‑2026 | Sale | 1,100 | ~$530 | ~$583 k | ~ 322,800 |
| 10‑20‑2026 | Sale | 1,000 | ~$540 | ~$540 k | ~ 321,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 320,600 |
| 10‑20‑2026 | Sale | 1,000 | ~$530 | ~$530 k | ~ 319,600 |
| 10‑20‑2026 | Sale | 1,100 | ~$545 | ~$599 k | ~ 318,500 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 317,300 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 316,100 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 314,900 |
| 10‑20‑2026 | Sale | 1,000 | ~$545 | ~$545 k | ~ 313,900 |
| 10‑20‑2026 | Sale | 1,000 | ~$540 | ~$540 k | ~ 312,900 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 311,700 |
| 10‑20‑2026 | Sale | 1,000 | ~$530 | ~$530 k | ~ 310,700 |
| 10‑20‑2026 | Sale | 1,100 | ~$545 | ~$599 k | ~ 309,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 308,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 307,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 306,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 304,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 303,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 302,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 301,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 300,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 298,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 297,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 296,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 295,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 294,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 292,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 291,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 290,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 289,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 288,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 286,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 285,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 284,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 283,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 282,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 280,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 279,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 278,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 277,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 276,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 274,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 273,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 272,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 271,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 270,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 268,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 267,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 266,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 265,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 264,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 262,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 261,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 260,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 259,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 258,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 256,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 255,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 254,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 253,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 252,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 250,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 249,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 248,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 247,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 246,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 244,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 243,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 242,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 241,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 240,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 238,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 237,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 236,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 235,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 234,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 232,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 231,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 230,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 229,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 228,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 226,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 225,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 224,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 223,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 222,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 220,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 219,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 218,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 217,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 216,000 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 214,800 |
| 10‑20‑2026 | Sale | 1,200 | ~$545 | ~$654 k | ~ 213,600 |
| 10‑20‑2026 | Sale | 1,200 | ~$540 | ~$648 k | ~ 212,400 |
| 10‑20‑2026 | Sale | 1,200 | ~$535 | ~$642 k | ~ 211,200 |
| 10‑20‑2026 | Sale | 1,200 | ~$530 | ~$636 k | ~ 210,000 |
The table above condenses the detailed filing entries; the actual SEC documents list each transaction individually.
Key Observations
- Net Position
- After the purchase of ~ 9,500 shares, Rothblatt’s stake rose to roughly 333,900 shares.
- Subsequent sales reduced her holding to just below 330,000 shares by the end of the reporting period, indicating a net outflow of ~ 3,900 shares.
- Price Range
- Purchases occurred at approximately $118 per share, a price substantially below the market levels during the reporting period, suggesting acquisition at a discount or pre‑market transaction.
- Sales were executed at $530–$550 per share, aligning with the company’s trading price near the close of each day, thereby reflecting market‑aligned disposals.
- Transaction Vehicle
- All trades were conducted through a trust, denoted by the ownership type “by Trust.” This structure is common for senior executives seeking to manage tax implications or regulatory compliance.
- Regulatory Compliance
- The filings specifically state that these changes are “not subject to Section 16 reporting requirements.” This designation typically applies when the trades are made through a trust, which can qualify as a “trust or fiduciary” under SEC rules, thus exempting the transactions from certain reporting thresholds.
- No Disclosed Corporate Actions
- The SEC documents include no additional remarks on dividend adjustments, corporate actions, or regulatory changes. The activity appears strictly limited to ordinary shareholding adjustments.
Analytical Context
Capital Allocation Strategy Rothblatt’s purchase at a lower price coupled with subsequent sales at market rates may reflect a personal investment strategy rather than an indication of corporate performance or future outlook.
Signal to Investors Insider buying is often interpreted as positive, yet the modest volume relative to the company’s market capitalization (United Therapeutics has an AUM‑like valuation of several billion dollars) limits the weight of this signal. The subsequent sell‑offs, executed at market levels, suggest routine portfolio rebalancing.
Comparative Industry Insight In biotech and life‑science companies, executives frequently hold significant share positions, but trading is usually more conservative. The relatively large sales volume here may stand out when compared to peers such as Illumina or Gilead, whose insiders typically trade in smaller batches.
Economic Implications The transactions occur amid a broader market environment characterized by elevated valuations for biotech firms. The purchase at $118 could reflect an expectation of long‑term appreciation, while the sales at $530–$550 might capture short‑term gains in a sector that remains sensitive to regulatory approvals and patent expirations.
Conclusion
The October 2026 SEC filings provide a clear record of Martine A. Rothblatt’s shareholding adjustments at United Therapeutics Corp. While the purchase of a relatively small block of shares at a discounted price and subsequent market‑aligned disposals suggest routine personal portfolio management, the activity does not signal any material change in corporate governance or strategic direction. Investors monitoring insider transactions should view these moves within the broader context of the
